JP5580535B2 - 癌転移および癌転移に関連する骨量減少を予防および処置するための方法 - Google Patents

癌転移および癌転移に関連する骨量減少を予防および処置するための方法 Download PDF

Info

Publication number
JP5580535B2
JP5580535B2 JP2008549592A JP2008549592A JP5580535B2 JP 5580535 B2 JP5580535 B2 JP 5580535B2 JP 2008549592 A JP2008549592 A JP 2008549592A JP 2008549592 A JP2008549592 A JP 2008549592A JP 5580535 B2 JP5580535 B2 JP 5580535B2
Authority
JP
Japan
Prior art keywords
antibody
csf
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008549592A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009522369A5 (enExample
JP2009522369A (ja
Inventor
マイケル カバナフ，
チェン リュー，
Original Assignee
ノバルティス アーゲー
ゾーマ テクノロジー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ゾーマ テクノロジー リミテッド filed Critical ノバルティス アーゲー
Publication of JP2009522369A publication Critical patent/JP2009522369A/ja
Publication of JP2009522369A5 publication Critical patent/JP2009522369A5/ja
Application granted granted Critical
Publication of JP5580535B2 publication Critical patent/JP5580535B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2008549592A 2006-01-05 2007-01-04 癌転移および癌転移に関連する骨量減少を予防および処置するための方法 Active JP5580535B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75694406P 2006-01-05 2006-01-05
US60/756,944 2006-01-05
PCT/US2007/000405 WO2007081879A2 (en) 2006-01-05 2007-01-04 Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012186613A Division JP2012229271A (ja) 2006-01-05 2012-08-27 癌転移および癌転移に関連する骨量減少を予防および処置するための方法

Publications (3)

Publication Number Publication Date
JP2009522369A JP2009522369A (ja) 2009-06-11
JP2009522369A5 JP2009522369A5 (enExample) 2011-02-10
JP5580535B2 true JP5580535B2 (ja) 2014-08-27

Family

ID=38219019

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008549592A Active JP5580535B2 (ja) 2006-01-05 2007-01-04 癌転移および癌転移に関連する骨量減少を予防および処置するための方法
JP2012186613A Pending JP2012229271A (ja) 2006-01-05 2012-08-27 癌転移および癌転移に関連する骨量減少を予防および処置するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012186613A Pending JP2012229271A (ja) 2006-01-05 2012-08-27 癌転移および癌転移に関連する骨量減少を予防および処置するための方法

Country Status (12)

Country Link
US (1) US20090246208A1 (enExample)
EP (2) EP1984024A2 (enExample)
JP (2) JP5580535B2 (enExample)
KR (1) KR20080083187A (enExample)
CN (1) CN101534858A (enExample)
AU (1) AU2007205048B2 (enExample)
BR (1) BRPI0706314A2 (enExample)
CA (1) CA2636149A1 (enExample)
IL (1) IL192568A0 (enExample)
RU (1) RU2470665C2 (enExample)
TW (1) TW200738262A (enExample)
WO (1) WO2007081879A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183207B2 (en) 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
WO2010062399A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Csf1r extracellular domain fusion molecules and treatments using same
PT2949670T (pt) 2009-12-10 2019-05-20 Hoffmann La Roche Anticorpos que se ligam preferencialmente ao domínio extracelular 4 do csf1r e respetiva utilização
CA2789071C (en) * 2010-03-05 2018-03-27 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
WO2011107553A1 (en) 2010-03-05 2011-09-09 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
CN107011438B (zh) 2010-05-04 2020-11-20 戊瑞治疗有限公司 结合csf1r的抗体
AU2012285875B2 (en) 2011-07-18 2016-11-10 Morphosys Ag Use of c-Fms antagonists
WO2013033206A2 (en) * 2011-08-29 2013-03-07 University Of Rochester Compositions and methods for inhibiting ccl3
RU2658603C2 (ru) 2011-12-15 2018-06-21 Ф.Хоффманн-Ля Рош Аг Антитела против человеческого csf-1r и их применения
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
CN103044555B (zh) * 2012-07-05 2016-08-31 雷克塞德（苏州）生物医药有限公司 包含cFms胞外片段的融合蛋白质及其制备方法和应用
SG10201906328RA (en) 2012-08-31 2019-08-27 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
CA2906394A1 (en) * 2013-03-15 2014-09-18 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
CN105121466A (zh) 2013-04-12 2015-12-02 莫佛塞斯公司 靶向m-csf的抗体
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
RU2551622C1 (ru) * 2014-02-20 2015-05-27 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения опухолей позвоночника
JP6964410B2 (ja) 2014-06-23 2021-11-10 ファイヴ プライム セラピューティクス インク コロニー刺激因子１受容体（ｃｓｆ１ｒ）に結合する抗体で疾患を治療する方法
LT3212670T (lt) 2014-10-29 2021-02-10 Five Prime Therapeutics, Inc. Kombinuotasis vėžio gydymas
ES2843586T3 (es) 2014-12-22 2021-07-19 Five Prime Therapeutics Inc Anticuerpos dirigidos contra CSF1R para tratar la SVNP
BR112017020952A2 (pt) 2015-04-13 2018-07-10 Five Prime Therapeutics Inc método de tratamento de câncer, composição e uso da composição
RU2609871C1 (ru) * 2015-08-10 2017-02-06 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Противоопухолевое средство
RU2631486C1 (ru) * 2016-06-17 2017-09-22 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" (ФБУН ГНЦ ВБ "Вектор") Способ получения противоопухолевого средства против метастазов костей в виде конъюгата белка-цитокина и аминобисфосфоната
EP3504239B1 (en) 2016-08-25 2024-05-29 F. Hoffmann-La Roche AG Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
EP3558360A1 (en) 2016-12-22 2019-10-30 F. Hoffmann-La Roche AG Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
KR20200051024A (ko) 2017-09-13 2020-05-12 파이브 프라임 테라퓨틱스, 인크. 췌장암에 대한 조합 항-csf1r 및 항-pd-1 항체 조합 요법
EP3833762A4 (en) 2018-08-09 2022-09-28 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4929700A (en) 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
DK0457804T3 (da) 1989-02-10 1996-09-23 Chiron Corp M-CSF-monoklonale antistoffer, som genkender en neutraliserende, konformational epitop
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
ATE249840T1 (de) * 1991-12-13 2003-10-15 Xoma Corp Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
US20020111461A1 (en) 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6025146A (en) 1995-06-05 2000-02-15 Chiron Corporation Identification of M-CSF agonists and antagonists
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
RU2153358C1 (ru) * 1999-11-10 2000-07-27 Центральный научно-исследовательский рентгенорадиологический институт МЗ России Способ лечения остеолитических метастазов
US20030199531A1 (en) 2001-07-19 2003-10-23 Todd Wipke YIGSR peptidomimetics and methods for using the same
JP2005516928A (ja) * 2001-12-13 2005-06-09 メルク　エンド　カムパニー　インコーポレーテッド 骨異常のためのビスホスホネート液体製剤
MXPA05003318A (es) * 2002-09-27 2005-09-12 Zentaris Gmbh Forma de administracion para peptidos farmaceuticamente activos con liberacion sostenida y metodo para la produccion de los mismos.
CA2505994A1 (en) * 2002-11-15 2004-06-03 Chiron Corporation Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
PT2311873T (pt) * 2004-01-07 2018-11-20 Novartis Vaccines & Diagnostics Inc Anticorpo monoclonal específico para m-csf e respetivos usos
JP5457671B2 (ja) * 2005-07-28 2014-04-02 ノバルティス アーゲー Ｍ−ｃｓｆ特異的モノクローナル抗体およびその使用
NZ572072A (en) * 2006-04-20 2011-09-30 Janssen Pharmaceutica Nv Inhibitors of c-fms kinase

Also Published As

Publication number Publication date
AU2007205048A1 (en) 2007-07-19
EP2705854A1 (en) 2014-03-12
TW200738262A (en) 2007-10-16
IL192568A0 (en) 2011-08-01
US20090246208A1 (en) 2009-10-01
KR20080083187A (ko) 2008-09-16
CN101534858A (zh) 2009-09-16
CA2636149A1 (en) 2007-07-19
WO2007081879A3 (en) 2007-09-07
JP2009522369A (ja) 2009-06-11
EP1984024A2 (en) 2008-10-29
BRPI0706314A2 (pt) 2011-03-22
RU2008132150A (ru) 2010-02-10
WO2007081879A2 (en) 2007-07-19
RU2470665C2 (ru) 2012-12-27
AU2007205048B2 (en) 2013-07-04
JP2012229271A (ja) 2012-11-22

Similar Documents

Publication Publication Date Title
JP5580535B2 (ja) 癌転移および癌転移に関連する骨量減少を予防および処置するための方法
US11407822B2 (en) Treatment of fibrodysplasia ossificans progressiva
ES2689328T3 (es) Anticuerpo monoclonal M-CSF-específico y usos del mismo
KR20200044957A (ko) Nkg2d, cd16 및 종양-연관 항원에 결합하는 단백질
CN113004391A (zh) 结合nkg2d、cd16和egfr、ccr4或pd-l1的蛋白质
CN120173123A (zh) 靶向caix、ano1、间皮素、trop2、cea或紧密连接蛋白-18.2的多特异性结合蛋白
KR20200051789A (ko) Nkg2d, cd16, 및 c-유형 렉틴-유사 분자-1 (cll-1)에 결합하는 단백질
KR20200010428A (ko) Nkg2d, cd16, 및 ror1 또는 ror2에 결합하는 단백질
KR20190120775A (ko) Cd33, nkg2d 및 cd16에 결합하는 단백질
KR20200010429A (ko) Nkg2d, cd16 및 종양-연관 항원에 결합하는 단백질
CN107530419A (zh) 治疗疾病的组合疗法
KR20200038530A (ko) Nkg2d, cd16 및 종양-연관 항원에 결합하는 단백질
BR112014028838A2 (pt) Usos de um anticorpo, método para fazer um anticorpo e anticorpos
BR112020004458A2 (pt) Anticorpo ou seu fragmento de ligação ao antígeno eao epítopo ou proteína de fusão, ácido nucleico, composição farmacêutica, e, usos de um anticorpo ou fragmento de ligação ao antígeno ou uma composição farmacêutica para preparar um medicamento para induzir, promover ou aumentar uma resposta imune, para tratar o câncer, para reduzir a carga tumoral e para tratar uma infecção em um sujeito em necessidade
KR20200143718A (ko) 이식편 거부반응 예방에 사용하기 위한 항-cd40 항체
JP2022514215A (ja) Ｒａｎｋアンタゴニストおよびその使用
US10941204B2 (en) Highly potent antibodies binding to death receptor 4
HK1195254A (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
MX2008008570A (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
CA2997130C (en) Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
HK1238260B (en) Treatment of fibrodysplasia ossificans progressiva
HK1238260A1 (en) Treatment of fibrodysplasia ossificans progressiva

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120327

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120626

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120703

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120726

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120827

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130227

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130306

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130329

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130426

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140501

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140523

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140701

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140711

R150 Certificate of patent or registration of utility model

Ref document number: 5580535

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250